CA2279488A1 - Anti-viral guanosine-rich tetrad forming oligonucleotides - Google Patents

Anti-viral guanosine-rich tetrad forming oligonucleotides Download PDF

Info

Publication number
CA2279488A1
CA2279488A1 CA002279488A CA2279488A CA2279488A1 CA 2279488 A1 CA2279488 A1 CA 2279488A1 CA 002279488 A CA002279488 A CA 002279488A CA 2279488 A CA2279488 A CA 2279488A CA 2279488 A1 CA2279488 A1 CA 2279488A1
Authority
CA
Canada
Prior art keywords
oligonucleotide
virus
hiv
viral
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002279488A
Other languages
English (en)
French (fr)
Inventor
Robert F. Rando
Joshua O. Ojwang
Michael E. Hogan
Thomas L. Wallace
Paul A. Cossum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Aronex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/987,574 external-priority patent/US6150339A/en
Application filed by Individual filed Critical Individual
Publication of CA2279488A1 publication Critical patent/CA2279488A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
CA002279488A 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides Abandoned CA2279488A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3737497P 1997-02-04 1997-02-04
US60/037,374 1997-02-04
US08/987,574 US6150339A (en) 1993-04-23 1997-12-09 Anti-viral guanosine-rich oligonucleotides
US08/987,574 1997-12-09
PCT/US1998/001974 WO1998033807A1 (en) 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides

Publications (1)

Publication Number Publication Date
CA2279488A1 true CA2279488A1 (en) 1998-08-06

Family

ID=26714074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279488A Abandoned CA2279488A1 (en) 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides

Country Status (4)

Country Link
EP (1) EP0971944A4 (de)
AU (1) AU6262598A (de)
CA (1) CA2279488A1 (de)
WO (1) WO1998033807A1 (de)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4388306A (en) * 1980-06-04 1983-06-14 Merck & Co., Inc. Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US5075217A (en) * 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
AU725936B2 (en) * 1995-07-19 2000-10-26 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides

Also Published As

Publication number Publication date
EP0971944A4 (de) 2005-01-26
AU6262598A (en) 1998-08-25
EP0971944A1 (de) 2000-01-19
WO1998033807A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
US6184369B1 (en) Anti-viral guanosine-rich oligonucleotides
US6323185B1 (en) Anti-viral guanosine-rich oligonucleotides and method of treating HIV
Ojwang et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1
Lisziewicz et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
US5523389A (en) Inhibitors of human immunodeficiency virus
EP1007657B1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
Matsukura et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.
Agrawal et al. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.
US5684147A (en) Therapeutic anti-HIV anti-viral oligonucleotides and pharmaceutical formulations thereof
ES2218522T3 (es) Oligonucleotidos estabilizados y su uso.
US6291438B1 (en) Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US6288042B1 (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
CA2194398A1 (en) Compounds and methods for inhibiting propagation of human immunodeficiency virus
AU725936B2 (en) Anti-viral guanosine-rich oligonucleotides
CA2180358A1 (en) Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2279488A1 (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1998033807A9 (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
Furukawa et al. Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5′ terminal by dimethoxytrityl residue
Fujihashi et al. Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus
WO2023089808A1 (ja) ＡＰＯＢＥＣ３Ｇ／Ｖｉｆ結合体形成阻害剤
WO2002068582A2 (en) Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
Momota et al. Antiviral and biological properties of dimethoxytrityl-linked guanine-rich oligodeoxynucleotides that inhibit replication by primary clinical human immunodeficiency virus type 1 isolates
Mitsuya et al. Toward the rational design of antiretroviral therapy for human immunodeficiency virus (HIV) infection
Tondelli et al. Native oligodeoxynucleotides specifically active against human immunodeficiency virus type 1 in vitro: a G-quartet-driven effect?
Bouchard et al. 5-Aza-cytosine derivative chemotherapy in AIDS

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued